SabioTrade’s One-Step Evaluation: What do we think of it?

Embarking on a trading journey can be both exhilarating and daunting, but SabioTrade’s One-step Evaluation is here to simplify the process and elevate your trading career. Imagine having the chance to manage accounts ranging from $20,000 to $200,000 with leverage up to 1:30, all while proving your mettle as a disciplined and profitable trader. This evaluation challenges you to achieve a 10% profit target without breaching strict risk management rules. If successful, you’ll get a funded account with the freedom to withdraw without minimum requirements. SabioTrade’s One-step Evaluation is not just a test; it’s an exciting gateway to professional trading.

SabioTrade’s One-Step Evaluation: What do we think of it?

SabioTrade’s One-step Evaluation provides traders with the opportunity to manage account sizes ranging from $20,000 up to $200,000. The aim is to identify disciplined traders who are profitable and can efficiently manage risk throughout a one-step evaluation period. The One-step Evaluation allows you to trade with leverage up to 1:30.

• The evaluation phase requires a trader to reach a profit target of 10% while not surpassing their 3% maximum daily loss or 6% maximum trailing loss rules. When it comes to time limitations, note that you have no minimum or maximum trading day requirements during phase one. To proceed to funded status, you have to reach the 10% profit target without breaching the maximum daily or maximum trailing loss limit rules.

By completing the evaluation phase, you are awarded a funded account with no minimum withdrawal requirements. You must only respect the 3% maximum daily loss and 6% maximum trailing loss rules.

Whether you’re an aspiring trader or looking to elevate your trading career, this evaluation provides a structured yet flexible path to success. Embrace the challenge, demonstrate your trading prowess, and unlock the potential for growth with SabioTrade.

So, use our Discount Code (FPX) for a 30% Discount or read the Review.